NASDAQ$SIGA
SIGA Technologies, Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
SIGA Technologies' Q3 2022 financial results were reported, showing significant international sales and diversification of revenue base.
SIGA Technologies reported strong Q3 2022 financial results, driven by significant international sales of oral TPOXX and diversification of its revenue base with new customers and product formulations. Total revenue reached $72.2 million, with a net income of $33.0 million and diluted earnings per share of $0.45.
- SIGA's Q3 2022 revenue was $72.2 million, compared to $4.8 million in Q3 2021.
- Operating income for Q3 2022 was $42.9 million, a significant increase from the $(2.9) million loss in Q3 2021.
- Net income for Q3 2022 was $33.0 million, compared to a net loss of $(3.1) million in Q3 2021.
- Diluted earnings per share for Q3 2022 were $0.45, compared to a loss per share of $(0.04) in Q3 2021.
Headline financials
Revenue & EPS history
SIGA Technologies · Revenue · Quarterly
$72.2M
Revenue by segment
SIGA Technologies · $72.2M total across 2 segments · Q3 2022
- Product Sales$65.6M+2697.0%90.9%
- R&D Revenues$6.59M+163.6%9.1%
Forward guidance
The company anticipates continued performance under existing contracts and is closely monitoring the monkeypox outbreak. However, the company acknowledges risks related to contract modifications, supply chain disruptions, and the impact of COVID-19 on operations.
Tailwinds
- Potential for further procurement orders related to the monkeypox outbreak.
- Continued performance under the BARDA contract.
- Ongoing clinical trials assessing TPOXX for monkeypox treatment.
- New procurement contract from the DoD for oral TPOXX.
- Exercise of procurement options by BARDA for IV TPOXX.
Headwinds
- Risk that BARDA may not exercise all remaining unexercised options under the BARDA Contract.
- Risk of not completing performance under the BARDA Contract on schedule or in accordance with contractual terms.
- Risk of modifications or cancellation of the BARDA Contract or DoD procurement contract at the request of the U.S. Government.
- Risk of disruptions to SIGA’s supply chain for the manufacture of TPOXX.
- Potential adverse effects from U.S. or foreign governments' responses to economic conditions or infectious diseases like COVID-19.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-0.2%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+2.4%
Avg return
30 days after
41%
26 / 64 earnings
Positive
+31.9%
Q4 2023
Best reaction
-27.8%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | -5.5% | -8.5% | |
| Q4 2025 | -3.0% | -3.4% | -22.8% | |
| Q3 2025 | -20.2% | -24.0% | -24.1% | |
| Q1 2025 | +4.4% | +9.0% | +10.8% | |
| Q4 2024 | +7.0% | +0.5% | +6.4% | |
| Q3 2024 | -1.9% | -8.5% | -9.8% | |
| Q2 2024 | -12.8% | -14.3% | -9.5% | |
| Q1 2024 | -27.8% | -28.2% | -26.7% | |
| Q4 2023 | +31.9% | +49.9% | +88.3% | |
| Q3 2023 | -4.4% | -2.2% | +16.9% | |
| Q2 2023 | -3.7% | -10.0% | -21.9% | |
| Q1 2023 | +5.1% | +1.8% | -0.7% | |
| Q4 2022 | -3.8% | -7.8% | -13.4% | |
| Q3 2022 | +7.5% | +9.8% | +1.1% | |
| Q2 2022 | +27.4% | +24.6% | -21.0% | |
| Q1 2022 | +3.6% | +4.0% | +60.7% | |
| Q4 2021 | +3.0% | +6.6% | +22.4% | |
| Q3 2021 | -0.7% | +0.0% | +2.8% | |
| Q2 2021 | -2.9% | -4.0% | +9.1% | |
| Q1 2021 | -0.7% | -8.4% | -10.4% | |
| Q4 2020 | +1.7% | +9.3% | +1.2% | |
| Q3 2020 | +2.0% | +3.4% | -0.9% | |
| Q2 2020 | +14.3% | +5.5% | -1.9% | |
| Q1 2020 | -1.4% | +1.4% | +2.9% | |
| Q4 2019 | +10.4% | +0.4% | +0.2% | |
| Q3 2019 | -3.2% | -1.8% | -19.8% | |
| Q2 2019 | +0.2% | -1.7% | +2.7% | |
| Q1 2019 | +1.5% | -1.3% | -12.8% | |
| Q4 2018 | -4.4% | -1.6% | -6.3% | |
| Q3 2018 | +8.4% | +5.7% | +29.1% | |
| Q2 2018 | +0.3% | +7.7% | +1.4% | |
| Q1 2018 | -0.5% | +2.4% | -3.9% | |
| Q4 2017 | -0.6% | -7.0% | -2.3% | |
| Q3 2017 | +2.8% | -1.1% | +3.9% | |
| Q2 2017 | -1.6% | -1.6% | -1.9% | |
| Q1 2017 | -0.3% | +0.6% | -8.0% | |
| Q4 2016 | -0.6% | +0.0% | -4.1% | |
| Q3 2016 | -5.7% | +3.8% | +54.8% | |
| Q2 2016 | +4.5% | +4.1% | +11.4% | |
| Q1 2016 | +1.1% | — | — | |
| Q4 2015 | +1.1% | — | — | |
| Q3 2015 | +2.4% | — | — | |
| Q2 2015 | -0.9% | — | — | |
| Q1 2015 | +5.7% | — | — | |
| Q4 2014 | -1.3% | — | — | |
| Q3 2014 | -0.7% | — | — | |
| Q2 2014 | -4.9% | — | — | |
| Q1 2014 | -1.4% | — | — | |
| Q4 2013 | -2.7% | — | — | |
| Q3 2013 | -3.5% | — | — | |
| Q2 2013 | -2.8% | — | — | |
| Q1 2011 | -2.4% | — | — | |
| Q4 2012 | -2.5% | — | — | |
| Q3 2012 | +6.5% | — | — | |
| Q2 2012 | +5.3% | — | — | |
| Q1 2012 | +4.5% | — | — | |
| Q4 2011 | -1.4% | — | — | |
| Q4 2009 | -1.4% | — | — | |
| Q3 2010 | -6.1% | — | — | |
| Q3 2011 | -6.1% | — | — | |
| Q2 2011 | -12.0% | — | — | |
| Q2 2010 | -12.0% | — | — | |
| Q4 2010 | -12.0% | — | — | |
| Q1 2010 | -1.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro